Applied BioCode (6598) — Cash Flow Reinvestment Rate

Latest as of September 2022: 2.85x

Applied BioCode (6598) has a Cash Flow Reinvestment Rate of 2.85x as of September 2022, reinvesting NT$18.11 Million (capex NT$12.00 Million plus investments NT$-6.11 Million) from operating cash flow of NT$6.35 Million. See Applied BioCode (6598) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

2.85x
(Capex + Investments) / Operating CF

Total Reinvested

NT$18.11 Million
Capex + Investments

Operating Cash Flow

NT$6.35 Million
TWD

Capital Expenditures

NT$12.00 Million
TWD

Applied BioCode Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Applied BioCode across 1 annual periods. For the full cash flow conversion analysis, see Applied BioCode cash flow conversion.

Annual Cash Flow Reinvestment Rate for Applied BioCode (2022–2022)

Year-by-year capital reinvestment analysis for Applied BioCode. See financial agility of Applied BioCode to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2022 0.30x NT$44.28 Million NT$145.87 Million NT$22.14 Million —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow